The FDA's platform technology designation for Sarepta's rAAVrh74 vector could boost its pipeline of gene therapies for limb-girdle muscular dystrophies. (Shutterstock)
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
